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Abstract: Coagulation is recognized as a key player in inflammatory and autoimmune diseases.
The aim of the current research was to examine the effect of pretreatment with acenocoumarol
on the development of acute pancreatitis (AP) evoked by cerulein. Methods: AP was induced in
rats by cerulein administered intraperitoneally. Acenocoumarol (50, 100 or 150 µg/kg/dose/day)
or saline were given once daily for seven days before AP induction. Results: In rats with
AP, pretreatment with acenocoumarol administered at the dose of 50 or 100 µg/kg/dose/day
improved pancreatic histology, reducing the degree of edema and inflammatory infiltration,
and vacuolization of acinar cells. Moreover, pretreatment with acenocoumarol given at the dose
of 50 or 100 µg/kg/dose/day reduced the AP-evoked increase in pancreatic weight, serum activity
of amylase and lipase, and serum concentration of pro-inflammatory interleukin-1β, as well as
ameliorated pancreatic DNA synthesis and pancreatic blood flow. In contrast, acenocoumarol
given at the dose of 150 µg/kg/dose did not exhibit any protective effect against cerulein-induced
pancreatitis. Conclusion: Low doses of acenocoumarol, given before induction of AP by cerulein,
inhibit the development of that inflammation.
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1. Introduction
There is close bidirectional relationship between coagulation and inflammation [1,2]. Inflammation
can be both a cause and a result of induction of coagulation [1–4]. Similarly, coagulation results not only
in thrombosis but also in activation of inflammatory process [1,2,5].
Acute pancreatitis (AP) is associated with coagulative disorders [6–9]. The stage of these
disorders depends on the severity of AP. Mild AP is associated with scattered intravascular thrombosis,
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whereas severe AP may lead to the development of disseminated intravascular coagulation [6–9].
Measurement of disseminated intravascular coagulation parameters is useful in the assessment of AP
severity and prediction for poor outcome of this disease at admission [7,8].
There are animal and clinical studies showing protective and therapeutic effect of a well-known
anticoagulant, heparin, in AP. Animals studies have indicated that pretreatment with heparin inhibits
the development of AP evoked by bile [9], taurocholate [10], cerulein [11] and pancreatic ischemia
followed by reperfusion [12]. Administration of heparin after induction of AP has been shown to
accelerate the recovery in acute pancreatitis evoked by cerulein [13] and pancreatic ischemia followed
by reperfusion [12].
Clinical reports suggests that pretreatment with heparin reduces frequency of post-ERCP
(endoscopic retrograde cholangiopancreatography) pancreatitis [14,15]. Moreover, treatment with
heparin given together with insulin is recommended as a gold standard in the management of
hyperlipidemia-induced AP [16–18]. Heparin has also been found to be effective in the prevention of
encephalopathy in the course of severe AP [19].
Mechanism of anticoagulant activity of heparin requires the presence of antithrombin III.
Antithrombin III is a protease inhibitor and complex heparin–antithrombin III inactivates thrombin
and active forms of clotting factors, IX, X, XI and XII, as well as inhibits the formation of thrombin and
active forms of clotting factors [20,21].
Observations concerning anti-inflammatory effects of heparin in AP led to the question whether
other anticoagulants such as coumarins also exhibit anti-inflammatory activity in this disease.
Coumarins are vitamin K antagonists. Reduced vitamin K is a necessary cofactor for the hepatic
γ-glutamyl carboxylase activity. That enzyme adds a carboxyl group to glutamic acid residues in
immature clotting factors II, VII, IX, and X as well as proteins S, C and Z. During activity of γ-glutamyl
carboxylase, vitamin K is oxidized. Coumarins inhibit the vitamin K epoxide reductase, an enzyme that
reduces vitamin K back to its active form. Coumarins reduce plasma levels of vitamin K-dependent
clotting factors causing a reduction in blood coagulability [21,22].
Our recent study has shown that inhibition of coagulation by pretreatment with low doses
of acenocoumarol, a drug from the group of coumarins, exhibits protective effect in the pancreas
leading to reduction of the severity of ischemia/reperfusion-induced AP [20]. On the other hand,
there are no data on whether protective effect of acenocoumarol in the pancreas depends on the
cause of AP or exhibits universal nature and occurs regardless of the primary agent causing this
inflammation. The effect of pretreatment with acenocoumarol on the development of AP evoked
by a primary non-vascular mechanism is unknown. Therefore, the aim of our present study was to
investigate whether the pretreatment with low doses of acenocoumarol affect the development of
cerulein-induced AP.
2. Results
In control saline-treated rats without induction of AP, international normalized ratio (INR)
reached a value of 1.08 ± 0.10 (Figure 1) while the average weight of the pancreas was 618 ± 22 g
(Figure 2). Morphological features showed that the pancreas in this group of animals exhibits
regular histology without damage of the gland (Figure 3 and Table 1). In rats without induction
of AP, administration of acenocoumarol given for seven days caused a dose-dependent increase
in INR (Figure 1). Acenocoumarol given at the dose of 50, 100 or 150 µg/kg/dose caused around
three-, four- and six-fold increase in INR, respectively. In these rats, acenocoumarol given at the
doses used did not cause a statistically significant effect on the weight of the pancreas (Figure 2),
pancreatic blood flow (Figure 4) and pancreatic DNA synthesis (Figure 5). In addition, serum activity
of lipase (Figure 6) and amylase (Figure 7), serum concentrations of interleukin-1β (IL-1β) (Figure 8),
and plasma D-dimer concentration (Figure 9) were not affected by acenocoumarol given in rats without
causing pancreatitis. Morphological features showed that acenocoumarol given alone caused in half
of cases slight interlobular edema of the pancreas (Table 1). Moreover, in contrast to lower doses,
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acenocoumarol given at the dose of 150 µg/kg/dose led to appear single hemorrhagic foci in pancreatic
tissue in half of animals without induction of pancreatitis (Table 1).
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Figure 1. Impact of pretreatment with acenocoumarol on the prothrombin time measured as 
international normalized ratio (INR) in rats with or without cerulein-induced pancreatitis. Key:  
C = control; AP = cerulein-induced acute pancreatitis; non-AP = groups without induction of acute 
pancreatitis; AC = acenocoumarol; 50 = 50 µg/kg/day; 100 = 100 µg/kg/day; 150 = 150 µg/kg/day. 



























Figure 2. Impact of pretreatment with acenocoumarol on the weight of the pancreas in rats with or 
without cerulein-induced pancreatitis. Key: C = control; AP = cerulein-induced acute pancreatitis; 
non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol; 50 = 50 µg/kg/day; 
100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats. a p < 0.05 
compared to control; b p < 0.05 compared to AP alone. 
 
Figure 3. Representative morphological images of the pancreas observed in control saline treated 
rats (A); rats pretreated with acenocoumarol given the dose of 50 µg/kg/day without induction of 
acute pancreatitis (B); rats with cerulein-induced acute pancreatitis (C); and rats pretreated with 
acenocoumarol (given the dose of 50 µg/kg/day) before induction of acute pancreatitis by cerulein 
(D). Hematoxylin–eosin counterstain, original magnification 200×. 
Figure 1. Impact of pretreatment with acenocoumarol on the prothrombin time measured
as international normalized ratio (INR) in rats with or without cerulein-induced pancreatitis.
Key: C = control; AP = cerulein-induced acute pancreatitis; non-AP = groups without induction of acute
pancreatitis; AC = acenocoumarol; 50 = 50 µg/kg/day; 100 = 100 µg/kg/day; 150 = 150 µg/kg/day.
Mean ± SEM. n = 10 in each group of rats. a p < 0.05 compared to control.
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100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats. a p < 0.05 
compared to control; b p < 0.05 compared to AP alone. 
 
Figure 3. Representative morphol gical images of t e pancreas observed in contr l saline reated
rats (A); rats pretreated with acenocoumarol given the dose of 50 µg/kg/day wi hout induction of
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Figure 2. Impact of pretreatment with acenocoumarol on the weight of the pancreas in rats
with or without cerulein-induced pancreatitis. Key: C = control; AP = cerulein-induced acute
pancreatitis; non-AP = groups without induction of acute pancreatitis; AC = cenocoumarol;
50 = 50 µg/kg/day; 100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group
of rats. a p < 0.05 compared to control; b p < 0.05 compared to AP alone.
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3A,B in [1]) are incorrect and, therefore, they need to be replaced with the correct new figure (Figure 1).  
 
Figure 1. Representative morphological images of the pancreas observed in control rats treated with 
saline (A); rats pretreated with acenocoumarol at the dose of 50 μg/kg/day without induction of acute 
Figure 1. Representative morphological images of the pancreas observed in control rats treated with
saline (A); rats pretreated with acenocoumarol at the dose of 50 µg/kg/day without induction of acute
pancreatitis (B); rats with cerulein-induced acute pancreatitis (C); rats pretreated with acenocoumarol
(given the dose of 50µg/kg/day) before induction of acute pancreatitis by cerulein (D). Hematoxylin-eosin
counterstain, original magnification 200×.
The reported error does not have any material impact on the final results and conclusions of our
published paper. We apologize for this inconvenient situation.
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Figure 3. R presentative morphologic l i ages of the pancreas observed in control rats treated
with saline (A); rats pretreated with acenocoumarol at the dose of 50 µg/kg/day without induction
of acute pa creatitis (B); rats with c rulein-induced cute pancreatitis (C); rats pretreated with
acenocoumarol (given the dose of 50 µg/kg/day) before induction of acute pancreatitis by cerulein (D).
Hematoxylin-eosin counterstain, original magnification 200×.
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Figure 4. Impact of pretreatment with acenocoumarol on pancreatic blood flow in rats with or 
without cerulein-induced pancreatitis. Key: C = control; AP = cerulein-induced acute pancreatitis; 
non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol; 50 = 50 µg/kg/day; 
100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats. a p < 0.05 
































Figure 5. Impact of pretreatment with acenocoumarol on pancreatic DNA synthesis in rats with or 
without cerulein-induced pancreatitis. Key: C = control; AP = cerulein-induced acute pancreatitis; 
non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol; 50 = 50 µg/kg/day; 
100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats. a p < 0.05 


























Figure 6. Impact of pretreatment with acenocoumarol on serum activity of lipase in rats with or 
without cerulein-induced pancreatitis. Key: C = control; AP = cerulein-induced acute pancreatitis; 
non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol; 50 = 50 µg/kg/day; 
100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats. a p < 0.05 
compared to control; b p < 0.05 compared to AP alone. 
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100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats.
a p < 0.05 compared to control; b p < 0.05 compared to AP alone.
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of rats. p < 0.05 compared to control; b p < 0.05 compared to AP alone.
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Figure 6. Impact of pretreat t it arol on serum activity of lipase in rats with or
without cerulein-induced pancreatiti . : control; AP = cerulein-induced acute pancreatitis;
no -AP = groups without induction of acute pancre titi ; ocoumarol; 50 = 50 µg/kg/day;
100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats.
a p < 0.05 compared to control; b p < 0.05 compared to AP alone.
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Figure 7. Impact of pretreatment with acenocoumarol on serum activity of amylase in rats with or 
without cerulein-induced pancreatitis. Key: C = control; AP = cerulein-induced acute pancreatitis; 
non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol; 50 = 50 µg/kg/day; 
100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats. a p < 0.05 






























Figure 8. Impact of pretreatment with acenocoumarol on serum concentration of interleukin-1β in 
rats with or without cerulein-induced pancreatitis. Key: C = control; AP = cerulein-induced acute 
pancreatitis; non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol;  
50 = 50 µg/kg/day; 100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of 























Figure 9. Impact of pretreatment with acenocoumarol on plasma D-Dimer concentration in rats with 
or without cerulein-induced pancreatitis. Key: C = control; AP = cerulein-induced acute pancreatitis; 
non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol; 50 = 50 µg/kg/day; 
100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats. a p < 0.05 
compared to control; b p < 0.05 compared to AP alone. 
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pancreatitis; non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol;
50 = 50 µg/kg/day; 100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group
of rats. p < 0.05 compared to control; b p < 0.05 compared to AP alone.
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Figure 8. Impact of pretreatment with acenocoumarol on serum concentration of interleukin-1β
in rats with or without cerulein-induced pancreatitis. Key: C = control; AP = cerulein-induced
acute pancreatitis; non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol;
50 = 50 µg/kg/day; 100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group
of rats. a p < 0.05 compared to control; b p < 0.05 compared to AP alone.
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100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats. a p < 0.05 
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Figure 9. Impact of pretreatment with acenocoumarol on plasma D-Dimer concentration in rats with 
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non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol; 50 = 50 µg/kg/day; 
100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group of rats. a p < 0.05 
compared to control; b p < 0.05 compared to AP alone. 
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pa creatitis; non-AP = groups without induction of acute pancreatitis; AC = acenocoumarol;
50 = 50 µg/kg/day; 100 = 100 µg/kg/day; 150 = 150 µg/kg/day. Mean ± SEM. n = 10 in each group
of rats. p < 0.05 compared to control; b p < 0.05 compared to AP alone.
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Table 1. Impact of pretreatment with acenocoumarol on histological signs of pancreatic damage in rats










Control 0 0 0 0 0
AP 2–3 1-2 3 0 0
AC 50 0–1 0 0 0 0
AC 100 0–1 0 0 0 0
AC 150 0–1 0 0 0 0-1
AC 50 + AP 1–2 1 2 0 0
AC 100 + AP 1–2 1 2 0 0
AC 150 + AP 3 1–2 2–3 0 1
Numbers represent the predominant histological grading in each experimental group. Key: Control = rats
without induction of AP or treatment with acenocoumarol; AP = cerulein-induced acute pancreatitis;
AC = acenocoumarol; 50 = 50 µg/kg/day; 100 = 100 µg/kg/day; 150 = 150 µg/kg/day.
Intraperitoneal administration of cerulein led to the development of edematous AP in all tested
rats (Table 1). Morphological features showed interlobular a moderate or severe intralobular edema.
This change was accompanied by a scare or moderate perivascular and scare diffuse inflammatory
leukocyte infiltration. Vacuolization was observed in more than 25% of acinar cells. Necrosis and
hemorrhage were not observed (Figure 3 and Table 1). Histological signs of pancreatic damage
were associated with functional and biochemical changes typically present in cerulein-induced AP.
The weight of the pancreas increased by 76% (Figure 2), while the pancreatic blood flow (Figure 4)
and pancreatic DNA synthesis (Figure 5) decreased by 45% and 40%, respectively. Intraperitoneal
administration of cerulein also resulted in more than an eight-fold increase in serum activity
of lipase (Figure 6) and more than a nine-fold increase in serum activity of amylase (Figure 7).
Serum concentration of pro-inflammatory IL-1β reached around 320% of a value observed in control
rats (Figure 8), whereas INR (Figure 1) and plasma D-Dimer concentration (Figure 9) increased
by 48% and 2350%, respectively.
Pretreatment with acenocoumarol given at the dose of 50 or 100 µg/kg/dose attenuated the
development of acute cerulein-induced pancreatitis. Histological examination showed a reduction in
pancreatic edema, inflammatory infiltration and vacuolization of acinar cells (Table 1 and Figure 3).
In addition, acenocoumarol given at the dose of 50 or 100 µg/kg/dose significantly decreased the
pancreatitis-evoked increase in pancreatic weight (Figure 2) serum activity of lipase (Figure 6) and
amylase (Figure 7), and serum concentration of pro-inflammatory IL-1β (Figure 9). These effects were
accompanied by a partial but statistically significant reversal of cerulein-induced decline in pancreatic
blood flow (Figure 4) and pancreatic DNA synthesis (Figure 5).
In contrast to effects of low doses of acenocoumarol, acenocoumarol given at the dose of
150 µg/kg/dose was without beneficial effect on the pancreatitis-evoked changes of pancreatic weight
(Figure 2), pancreatic blood flow (Figure 4), pancreatic DNA synthesis (Figure 5) serum activity of
pancreatic enzymes (Figures 6 and 7) and serum concentration of IL-1β (Figure 8). Morphological
features showed that pretreatment with acenocoumarol given at the dose of 150 µg/kg/dose was
without beneficial effect on the pancreatitis-evoked pancreatic inflammatory infiltration (Table 1).
Moreover, pretreatment with acenocoumarol given at the dose of 150 µg/kg/dose increased the
pancreatitis-evoked pancreatic edema and number of hemorrhages. Only the number of acinar cells
with signs of vacuolization was partially reduced (Table 1).
As in animals without pancreatitis, pretreatment with acenocoumarol resulted in dose dependent
increase in INR (Figure 1). Acenocoumaral given at all doses used caused a similar and statistically
significant reduction in the pancreatitis-evoked increase in plasma D-Dimer concentration (Figure 9).
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3. Discussion
In our present study, we investigated the impact of pretreatment with acenocoumarol on the
development of cerulein-induced AP in rats. This experimental model of AP leads to the development
of mild edematous pancreatitis evoked by primary non-vascular mechanism [23]. To our knowledge,
our investigation is the first report showing that low doses of acenocoumarol exhibit a protective
effect on the pancreas in AP evoked by cerulein. Importantly, our observation has been supported by
histological, functional and biochemical evidence.
The beneficial effect of pretreatment with low doses of acenocoumarol in rats with AP was
manifested by a reduction in morphological signs of pancreatic damage including pancreatic edema,
vacuolization of acinar cells and inflammatory leukocyte infiltration of pancreatic tissue. A reduction in
pancreatic edema was also found as a decrease in the pancreatitis-evoked increase in pancreatic weight.
Previous studies have shown that the onset of AP is associated with accumulation of leukocytes within
the pancreas and initiation of the local inflammatory response. Activation of neutrophils leads to their
adhesion to endothelial cells in pancreatic microcirculation causing the reduction in pancreatic blood
flow, inflammatory infiltration of pancreatic tissue and production of pro-inflammatory cytokines
within this organ [24–26]. In severe cases of AP, it leads to the development of necrotizing AP,
systemic inflammatory response syndrome (SIRS) and multiple organ failure (MOF) [27].
In our present study, acenocoumarol-related reduction in the inflammatory leukocyte infiltration
of pancreatic tissue in rats with AP was in harmony with a decrease in serum concentration of
interleukin-1β (IL-β). Activation of leukocytes leads to the release of pro-inflammatory cytokines and is
responsible for the development of local and systemic inflammatory response in AP, as well as may lead
to chronic inflammation and promotion of pancreatic fibrosis [28,29]. The level of pro-inflammatory
cytokines affects the severity of AP [28]. IL-1β plays a key role in the induction of local inflammatory
response and systemic acute phase response [30]. This cytokine stimulates the release of next members
of pro-inflammatory cascade, such as tumor necrosis factor-α (TNF-α), platelet-activating factor,
prostaglandins and other pro-inflammatory interleukins [28–30]. The important role of leukocyte
activation and IL-1β release in development and course of AP has been additionally evidenced by
observation that administration of IL-1 receptor antagonist prevents a serum rise in IL-6 and TNF-α,
and decreases the severity of AP [31]. In our present study, similarly to other previous reports [28,32,33],
we have detected the increase in serum levels of IL-1β in rats with AP. We have also found that
pretreatment with low doses of acenocoumarol resulted in a significant reduction of serum IL-1β
concentration and limitation of AP severity. These important findings are consistent with an earlier
report on the acenocoumarol-related reduction in IL-1β release in ischemia/reperfusion-induced AP
and indicate that acenocoumarol is a universal protective agent in AP [34].
The increase in serum activity of pancreatic digestive enzymes, lipase and amylase is a well-known
index of AP severity with high sensitivity and specificity [35,36]. In our present study, rats with
cerulein-induced pancreatitis demonstrated an eight- and nine-fold increase in serum activity of
lipase and amylase, respectively, compared to the control. Pretreatment with acenocoumarol given
at the dose of 50 or 100 µg/kg/day reduced the pancreatitis-evoked increase in serum activity of
lipase and amylase. This effect seems to be a result and, at least in part, a mechanism of protective
properties of acenocoumarol in the pancreas. Study performed by Keck et al. [37] showed that presence
of active pancreatic digestive enzymes in the circulation up-regulates the expression of adhesion
molecules on leukocytes and endothelial cells, leading to increase in leukocyte-endothelial interaction
and disturbance pancreatic microcirculation.
In harmony with our histological and biochemical observations supporting the protective impact
of acenocoumarol on the pancreas in cerulein-induced acute AP is its effect on pancreatic DNA
synthesis. DNA synthesis is an index of cell vitality and proliferation. Reduction in pancreatic DNA
synthesis is well-correlated with pancreatic damage in acute pancreatitis [38–40]. In our present
study, acenocoumarol given alone without induction of AP was without effect on pancreatic DNA
synthesis. This observation indicates that acenocoumarol given alone in doses used does not affect
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pancreatic cell vitality and proliferation. Induction of AP by cerulein administration led to reduction of
pancreatic DNA synthesis by around 45% and this effect was reversed by pretreatment with low doses
of acenocoumarol. This our result is similar to that observed in rats pretreated with acenocoumarol
before induction of AP evoked by pancreatic ischemia followed by reperfusion [34] showing that
pancreatoprotective effect of acenocoumarol is independent of primary cause of AP.
Disorders in pancreatic microcirculation are observed in all cases of AP, independently to
a primary etiology of this disease. Subsequently, it leads to activation of leukocytes and clotting
in pancreatic blood vessels, as well as to liberation of pro-inflammatory cytokines and pancreatic
digestive enzymes [26,41–44]. Microvascular impairment in the course of AP may be limited to
pancreatic circulation, but very often it occurs within the microcirculation of other organs such as
the kidney, lung, colon or liver [44]. On the other hand, the improvement of pancreatic blood flow
inhibits the development of acute pancreatitis and accelerates the recovery in this disease [45–47].
In the present study we have confirmed that cerulein-induced AP decreases pancreatic blood
flow. Our study has shown that pretreatment with acenocoumarol, given at the low dose of 50 or
100 µg/kg/day, improves pancreatic blood flow in rats exposed to cerulein and this effect has been
associated with reduction of severity of pancreatic damage. This observation indicates that protective
effect of acenocoumarol in cerulein-induced acute pancreatitis involves improvement of pancreatic
microcirculation. However, this effect seems to be secondary and related to anticoagulant activity
of acenocoumarol.
Vitamin K is necessary for the correct synthesis of prothrombin and three other plasma-clotting
factors, factor VII, IX and X. Normally, precursors of these clotting factors undergoes posttranslational
carboxylation by γ-glutamyl-carboxylase in liver microsomes prior to secretion into plasma.
The activity of y-glutamyl carboxylase requires the presence of vitamin K hydroquinone, which is
oxidized to vitamin K epoxide during carboxylation of precursors of coagulation factors. Vitamin K
epoxide is than reconverted to a reduced form of vitamin K by vitamin K epoxide reductase.
Acenocoumarol, as other vitamin K antagonists act as a competitive inhibitor of vitamin K reductase,
leading to reduction in a plasma level of functional precursors of vitamin K-dependent clotting factors
and the appearance, in the circulation, of biologically inactive precursors known as protein induced by
vitamin K absence/antagonist-II (PIVKA-II) or des-γ carboxyprothrombin (DCP) [48,49].
Activation of coagulation has been shown to stimulate the inflammatory responses by the
presence of active clotting factors (especially thrombin, factor Xa and tissue factor-factor VIIa complex),
mediators released from platelets and promotion of cell-cell interaction [1–3]. Acenocoumarol,
as other vitamin K antagonists, decreases the liver production of prothrombin and reduces
formation of thrombin after induction of coagulation. Thrombin promotes blood coagulation,
but it also serves as a signaling molecule by binding to protease-activated receptors (PARs) [50,51].
The presence of PARs has been found inter alia on platelets, endothelial cells, and also various
immune cells such as lymphocytes, macrophages, monocytes, dendritic cells and mast cells [50–52].
In platelets, pro-inflammatory effect of thrombin is related to alteration of platelets shape to
active phenotype and release of platelet factors. Furthermore, thrombin liberates the fibrinogen
receptor GPIIb-IIIa integrin complex and P-selectin, as well as mobilizes the CD40 ligand to the
platelet surface. Moreover, CD40 ligand induces endothelial cells to secrete chemokines and to
express adhesion molecules, leading to generation of signals for recruitment and extravasation
of leukocytes [51]. Acting directly on PARs on endothelial cells, thrombin and other proteases of
the coagulation-fibrinolysis system change shape of these cells into a pro-inflammatory phenotype,
increase vascular permeability, mobilize adhesive molecules and stimulate the production of cytokines
leading to the local accumulation of platelets and leukocytes [52]. In addition, fibrinolytic proteases
exhibit pro-inflammatory effects. Plasmin forms fibrin degradation products, which acting on toll-like
receptor-4 (TLR-4) can release latent matrix-bound growth factors. Furthermore, proteases that
convert plasminogen into plasmin, such as urokinase plasminogen activator (uPA), demonstrate the
plasmin-independent pro-inflammatory action by binding to their receptors and co-receptors [5].
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Induction of AP by cerulein led to increase in INR and plasma D-Dimer concentration.
This observation indicates that development of edematous cerulein-induced AP is associated with
activation of coagulation and formation of thrombi within the circulation, and this process is followed
by fibrinolysis. This finding is in harmony with previous animal and clinical studies showing that
AP activates coagulation and may lead to the development of consumptive coagulopathy [6,53,54].
D-Dimer is a product of plasmin-induced degradation of stabilized fibrin [55,56] and for this reason it
is recognized as a marker of fibrinolysis activation [7,54,57].
Our study has shown that pretreatment with acenocoumarol dose-dependently increases INR
and this effect reached a similar rate in animals with or without subsequent induction of AP. On the
other hand, pretreatment with acenocoumarol significantly reduced the pancreatitis-evoked increase in
plasma D-Dimer concentration. These findings indicate that pretreatment with acenocoumarol reduces
the level of clotting factors in plasma and decreases the activation of coagulation during induction
of AP. It inhibits formation of thrombin and reduces creation of D-Dimer, a product of fibrinolysis.
In contrast to protective effects of acenocoumarol given at the dose of 50 or 100 µg/kg/day,
our present study has shown that administration of this vitamin K antagonist at the dose of
150 µg/kg/day doses not exhibit any protective effect against the development of cerulein-induced AP.
This finding is most likely a result of excessive reduction in blood coagulation leading to excavation of
blood from blood vessels and disturbance of general and organ circulation. This concept is supported
by our present observation that pretreatment with acenocoumarol given at the dose of 150 µg/kg/day
causes a five-fold increase in INR. Lack of protective effect of pretreatment with acenocoumarol
given at the dose of 150 µg/kg/day is also in harmony with previous observation that this dose of
acenocoumarol does not prevent the development of ischemia/reperfusion-induced AP [34].
From the clinical point of view, the protective effect of acenocoumarol in acute pancreatitis
could be useful in preventing the development of acute pancreatitis following endoscopic retrograde
cholangiopancreatography (ERCP). ERCP, as an invasive procedure, carries a significant risk to the
patients. Post-ERCP complication rate vary widely depending on the complexity of the procedure
and the predisposition of the patient. Acute pancreatitis is the most frequent complication of
ERCP, which is reported to occur in 2%–10% of unselected patients and up to 8%–40% in high-risk
patients [58–60]. Apart from acute pancreatitis, other relatively frequent post-ERCP complications
are hemorrhage, cholangitis and perforation [58,60]. Post-ERCP bleeding has been reported in up
to 4.5% of patients [58,60]. Several studies have suggested that defined risk factors for bleeding
are coagulopathy, anticoagulation within three days of sphincterotomy, cholangitis before ERCP
and bleeding during initial endoscopic sphincterotomy [58]. Our current study has shown that
acenocoumarol given at the dose 50 µg/kg/dose increases INR to 3. This value is associated with
some risk of bleeding. Those findings may suggest that the possibility of the use of acenocoumarol in
the prevention of ERCP-induced pancreatitis is questionable. On the other hand, there is the study
showing that in multivariate analysis anticoagulants are not a statistically significant independent risk
factor for post-ERCP bleeding [60]. These data indicate that the potential utility of acenocoumarol in
the prevention of post-ERCP pancreatitis is ambiguous and needs further research in this area.
4. Materials and Methods
4.1. Animals and Treatment
All studies followed an experimental protocol approved by the Committee for Research and
Animal Ethics of the Jagiellonian University and the First Local Commission of Ethics for the Care and
Use of Laboratory Animals in Cracow (Permit Number 4/2013 released on 16 January 2013).
Studies were carried out on 80 male Wistar rats weighing 160–180 g, which were housed in cages
with wire-mesh bottoms in a windowless colony room. Temperature was adjusted at 22 ± 1 ◦C with
relative humidity of 50% ± 10%, and 12 h:12 h light:dark photoperiod. During the study animals had
free access to food and water.
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Following a one-week period of acclimation to their new environment, rats were randomly
divided into eight equal experimental groups: (1) saline-treated control rats; (2) rats with
cerulein-induced AP; (3–5) rats without induction of AP pretreated with acenocoumarol given at
the dose of 50, 100 or 150 µg/kg/dose; and (6–8) rats pretreated with acenocoumarol given at the dose
of 50, 100 or 150 µg/kg/dose before induction of AP by cerulein administration.
AP was induced by cerulein (Sigma-Aldrich, GmbH, Steinheim, Germany) given intraperitoneally
(i.p.) 5 times with 1 h intervals at a dose of 50 µg/kg per injection (group 2, 6, 7 and 8). At the same
time, animals from groups without induction of AP were treated i.p. with saline (group 1, 3, 4 and 5).
Acenocoumarol (Acenocumarol WZF, Warszawskie Zakłady Farmaceutyczne Polfa S.A., Warsaw,
Poland) at the dose of 50, 100 or 150 µg/kg/dose was administered intragastrically (i.g.) once a day
for 7 day before induction of AP (group 6, 7 and 8) or before intraperitoneal administration of saline
(rats without induction of AP: group 3, 4 and 5). Animals without administration of acenocoumarol
were treated i.g. for 7 days with saline. Acenocoumarol was given at the dose of 50, 100 or
150 µg/kg/dose because previous studies [34] showed that these doses caused an increase of
international normalized ratio (INR) to a range between 2.5 and 3.5. This value of INR is recommended
in the most clinical conditions related to coagulation disorders [61].
4.2. Determination of Pancreatic Blood Flow
Immediately after the last i.p. injection of cerulein or saline, rats were anesthetized with ketamine
(50 mg/kg i.p., Bioketan, Vetoquinol Biowet, Gorzów Wielkopolski, Poland) and experiment was
terminated. After opening the abdominal cavity the pancreas was exposed and blood flow in this
organ was determined using a laser Doppler flowmeter (PeriFlux 4001 Master Monitor, Perimed AB,
Järfälla, Sweden) in accordance with the method described previously in detail [62,63]. Data were
presented as percent change from value obtained in control saline-treated rats without induction of AP.
4.3. Biochemical Analysis
After the measurement of pancreatic blood flow, blood samples were taken from the abdominal
aorta. The prothrombin time measured as international normalized ratio (INR) was determined in fresh
blood, using Alere INRatio® 2 PT/INR Monitoring Systems and Alere INRatio® PT/INR Monitoring
System Test Strips (Alere San Diego, Inc., San Diego, CA, USA).
Plasma D-Dimer concentration was determined using an immunoturbidimetric assay (Innovance
D-Dimer Assay, Simens Healthcare GmbH, Marburg, Germany) on automatic coagulation analyzer
BCS XP System (Simens Healthcare Diagnostics, Erlangen, Germany).
Serum lipase and amylase activity was determined with a Kodak Ectachem DT II System analyzer
(Eastman Kodak Company, Rochester, NY, USA) using Lipa and Amyl DT Slides (Vitros DT Chemistry
System, Johnson & Johnson Clinical Diagnostic, Inc., Rochester, NY, USA).
Serum concentration of interleukin-1β (IL-1β) was measured using the Rat IL-1β Platinum Elisa
(Bender MedSystem GmbH, Vienna, Austria).
4.4. Determination of Pancreatic DNA Synthesis
After blood collection, the pancreas was cut out from its atachment to other organs and
weighed. Samples of pancreatic tissue were collected for determination of pancreatic DNA synthesis
and histological examination. The rate of pancreatic DNA synthesis was measured by assessing
the incorporation of labeled thymidine ((6-3H)-thymidine, 20–30 Ci/mmol, Institute for Research,
Production and Application of Radioisotopes, Prague, Czech Republic) into DNA, as described
previously in detail [64,65]. Rate of DNA synthesis was expressed as disintegrations of labeled
thymidine per minute per microgram DNA (dpm/µg DNA).
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4.5. Histological Examination of Pancreatic Damage
Microscopic examination of pancreatic tissue damage was performed in hematoxylin and
eosin (H&E) stained slides by two experienced pathologists as described previously in detail [66].
Histological grading of pancreatic edema, leukocyte inflammatory infiltration, vacuolization of acinar
cells, hemorrhages, and pancreatic necrosis was made using a scale ranging from 0 to 3. Results of
microscopic examination of the pancreas were expressed as the most frequent histological score (mode)
in each experimental group.
4.6. Statistical Analysis
Statistical analysis was made by analysis of variance followed by Tukey’s multiple comparison
test using GraphPadPrism (GraphPad Software, San Diego, CA, USA). The results were presented as
means ± SEM. Each experimental group consisted of ten animals. A difference with a p value of less
than 0.05 was considered significant.
5. Conclusions
In conclusion, we can say that results of our present experiments have indicated that low doses of
acenocoumarol exerts a pronounced protective effect on the pancreas and inhibits the development of
cerulein-induced AP. These findings taken together with a previous report showing preventive effect
of low doses of acenocoumarol in ischemia/reperfusion-induced AP indicate that protective effect of
low doses of acenocoumarol in the pancreas is universal and independent of the primary cause of AP.
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38. Dembinski, A.; Warzecha, Z.; Ceranowicz, P.; Dembiński, M.; Cieszkowski, J.; Pawlik, W.W.; Konturek, S.J.;
Tomaszewska, R.; Hładki, W.; Konturek, P.C.; et al. Cannabinoids in acute gastric damage and pancreatitis.
J. Physiol. Pharmacol. 2006, 57, 137–154. [PubMed]
39. Dembinski, A.; Warzecha, Z.; Ceranowicz, P.; Warzecha, A.M.; Pawlik, W.W.; Dembiński, M.; Rembiasz, K.;
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